FDA Warns Abbott COVID-19 Test May Return False Negatives
The US FDA issued an alert cautioning the public that Abbott’s widely used rapid test for detecting coronavirus has been linked to false-negative results.
You may also be interested in...
The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.